Research led by the University of California San Diego provides the first human evidence that semaglutide, the active ingredient in several widely used weight-loss drugs, can slow DNA markers linked to biological aging, especially in people living with HIV.
- Semaglutide slows DNA markers associated with aging in adults with HIV.
- GLP-1 drugs may reduce inflammation and harmful visceral fat.
- Findings could have wider implications beyond the HIV community.
What happened
In a randomized clinical trial involving 108 adults with HIV-associated lipohypertrophy, participants received weekly semaglutide injections or a placebo. Researchers used epigenetic clocks—tools that measure DNA methylation patterns—to assess biological aging, focusing on changes in gene regulation linked to aging processes. Those treated with semaglutide showed slower accumulation of DNA markers that typically indicate accelerated aging.
The study, published in Nature Communications, represents the first placebo-controlled evidence in humans that semaglutide may influence aging biology. The trial focused on adults living with HIV, a group known to experience faster biological aging due to chronic immune activation and fat accumulation around internal organs.
Why it feels good
Semaglutide and related GLP-1 medications help improve metabolic health, reduce inflammation, and lower harmful visceral and ectopic fat stores. These processes reduce chronic immune system activation, a driving factor in accelerated aging, especially for people with HIV. By targeting these interconnected pathways, the drug may slow some biological aging rhythms.
Beyond weight loss, these findings offer hope that existing medications can also increase healthspan—the years one remains healthy and disease-free. Although not reversing aging, semaglutide might ease age-associated cellular changes, potentially benefiting a broader population as aging mechanisms overlap between those living with HIV and the general public.
What to enjoy or watch next
While encouraging, the current evidence is preliminary and specific to a particular subgroup. Researchers call for larger, longer-term trials to confirm these benefits, explore how different GLP-1 based therapies perform in aging biology, and identify which patient groups gain the most advantage.
New developments in GLP-1 drug formulations are emerging, and ongoing studies may reveal further effects on aging pathways. Anyone interested in extending their healthspan should watch for future clinical results that might broaden how these common medications can support aging well.